141 related articles for article (PubMed ID: 11564695)
21. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.
Robling AG; Kedlaya R; Ellis SN; Childress PJ; Bidwell JP; Bellido T; Turner CH
Endocrinology; 2011 Aug; 152(8):2963-75. PubMed ID: 21652726
[TBL] [Abstract][Full Text] [Related]
22. Strong effect of PTH (1-34) on regenerating bone: a time sequence study in rats.
Skripitz R; Andreassen TT; Aspenberg P
Acta Orthop Scand; 2000 Dec; 71(6):619-24. PubMed ID: 11145391
[TBL] [Abstract][Full Text] [Related]
23. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation.
Zhao G; Monier-Faugere MC; Langub MC; Geng Z; Nakayama T; Pike JW; Chernausek SD; Rosen CJ; Donahue LR; Malluche HH; Fagin JA; Clemens TL
Endocrinology; 2000 Jul; 141(7):2674-82. PubMed ID: 10875273
[TBL] [Abstract][Full Text] [Related]
24. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH.
Sato M; Vahle J; Schmidt A; Westmore M; Smith S; Rowley E; Ma LY
Endocrinology; 2002 Sep; 143(9):3230-42. PubMed ID: 12193534
[TBL] [Abstract][Full Text] [Related]
25. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice.
Miyakoshi N; Richman C; Qin X; Baylink DJ; Mohan S
Endocrinology; 1999 Dec; 140(12):5719-28. PubMed ID: 10579337
[TBL] [Abstract][Full Text] [Related]
26. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
[TBL] [Abstract][Full Text] [Related]
27. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone.
Koh AJ; Demiralp B; Neiva KG; Hooten J; Nohutcu RM; Shim H; Datta NS; Taichman RS; McCauley LK
Endocrinology; 2005 Nov; 146(11):4584-96. PubMed ID: 16081645
[TBL] [Abstract][Full Text] [Related]
28. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I.
Staal A; Geertsma-Kleinekoort WM; Van Den Bemd GJ; Buurman CJ; Birkenhäger JC; Pols HA; Van Leeuwen JP
J Bone Miner Res; 1998 Jan; 13(1):36-43. PubMed ID: 9443788
[TBL] [Abstract][Full Text] [Related]
29. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
[TBL] [Abstract][Full Text] [Related]
30. Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model.
Lane NE; Kimmel DB; Nilsson MH; Cohen FE; Newton S; Nissenson RA; Strewler GJ
J Bone Miner Res; 1996 May; 11(5):614-25. PubMed ID: 9157776
[TBL] [Abstract][Full Text] [Related]
31. The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice.
Johnston S; Andrews S; Shen V; Cosman F; Lindsay R; Dempster DW; Iida-Klein A
Endocrinology; 2007 Sep; 148(9):4466-74. PubMed ID: 17569757
[TBL] [Abstract][Full Text] [Related]
32. Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I.
Kostenuik PJ; Harris J; Halloran BP; Turner RT; Morey-Holton ER; Bikle DD
J Bone Miner Res; 1999 Jan; 14(1):21-31. PubMed ID: 9893062
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo.
Merciris D; Marty C; Collet C; de Vernejoul MC; Geoffroy V
Am J Pathol; 2007 May; 170(5):1676-85. PubMed ID: 17456773
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats.
Hock JM; Fonseca J; Gunness-Hey M; Kemp BE; Martin TJ
Endocrinology; 1989 Oct; 125(4):2022-7. PubMed ID: 2791976
[TBL] [Abstract][Full Text] [Related]
35. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone.
Wang Y; Nishida S; Boudignon BM; Burghardt A; Elalieh HZ; Hamilton MM; Majumdar S; Halloran BP; Clemens TL; Bikle DD
J Bone Miner Res; 2007 Sep; 22(9):1329-37. PubMed ID: 17539737
[TBL] [Abstract][Full Text] [Related]
36. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.
Ma YL; Zeng Q; Donley DW; Ste-Marie LG; Gallagher JC; Dalsky GP; Marcus R; Eriksen EF
J Bone Miner Res; 2006 Jun; 21(6):855-64. PubMed ID: 16753016
[TBL] [Abstract][Full Text] [Related]
37. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.
Samadfam R; Xia Q; Goltzman D
J Bone Miner Res; 2007 Jan; 22(1):55-63. PubMed ID: 17014384
[TBL] [Abstract][Full Text] [Related]
38. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats.
Machwate M; Zerath E; Holy X; Pastoureau P; Marie PJ
Endocrinology; 1994 Mar; 134(3):1031-8. PubMed ID: 8119139
[TBL] [Abstract][Full Text] [Related]
40. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.
Kostenuik PJ; Capparelli C; Morony S; Adamu S; Shimamoto G; Shen V; Lacey DL; Dunstan CR
Endocrinology; 2001 Oct; 142(10):4295-304. PubMed ID: 11564687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
